Argenica Therapeutics Ltd (AU:AGN)
ASX:AGN
Want to see AU:AGN full AI Analyst Report?
AGN Stock Chart & Stats
AU$0.18
<AU$0.01(0.81%)
At close: 4:00 PM EST
AU$0.18
<AU$0.01(0.81%)
Day’s Range― - ―
52-Week RangeAU$0.13 - AU$0.85
Previous CloseN/A
Volume9.34K
Average Volume (3M)511.75K
Market Cap
AU$17.34M
Enterprise ValueAU$12.95M
Total Cash (Recent Filing)AU$10.56M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding128,456,710
10 Day Avg. Volume288,263
30 Day Avg. Volume511,745
Financial Highlights & Ratios
PEG Ratio-2.24
Price to Book (P/B)13.39
Price to Sales (P/S)30.16
P/FCF Ratio-16.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)AU$27.40M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure reduces solvency risk and preserves financial flexibility over the medium term. For a clinical-stage biotech this lowers fixed financing costs, eases ability to negotiate non-dilutive grants or strategic partnerships, and provides downside protection while trials progress.
Recent Revenue ScalingConsecutive revenue growth signals early commercial or milestone traction and demonstrates some product or collaboration validation. Sustainable top-line expansion improves runway management options, strengthens partner negotiations, and can reduce reliance on equity raises if the trend continues.
Focused Lead Program Addressing Unmet NeedA clear, single-product focus on neuroprotection addresses a large unmet clinical market and concentrates R&D resources. This strategic clarity supports efficient trial design, targeted regulatory planning, and makes the company an attractive licensing or partnering target if clinical data validate the mechanism.
Bears Say
Persistent Negative Cash FlowRecurring negative operating and free cash flows mean the business cannot self-fund development. Over a 2–6 month horizon this structural cash burn necessitates external capital or partnerships, raising execution risk and increasing the likelihood of dilutive financing if internal improvements don't materialize.
Deep And Widening LossesVery large negative margins reflect that costs substantially exceed revenues, making profitability distant absent major revenue expansion or cost restructuring. Persistent deep losses strain equity and make long-term planning reliant on external funding or strategic deals, limiting operational autonomy.
Sharply Reduced EquityA halving of shareholder equity materially reduces the balance-sheet buffer available to absorb further losses. This increases the probability and urgency of capital raises, which can be dilutive and constrain strategic flexibility during critical clinical development stages, heightening execution risk.
Argenica Therapeutics Ltd News
AGN FAQ
What was Argenica Therapeutics Ltd’s price range in the past 12 months?
Argenica Therapeutics Ltd lowest share price was AU$0.13 and its highest was AU$0.85 in the past 12 months.
What is Argenica Therapeutics Ltd’s market cap?
Argenica Therapeutics Ltd’s market cap is AU$17.34M.
When is Argenica Therapeutics Ltd’s upcoming earnings report date?
Argenica Therapeutics Ltd’s upcoming earnings report date is Mar 02, 2027 which is in 285 days.
How were Argenica Therapeutics Ltd’s earnings last quarter?
Argenica Therapeutics Ltd released its earnings results on Feb 10, 2026. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.03.
Is Argenica Therapeutics Ltd overvalued?
According to Wall Street analysts Argenica Therapeutics Ltd’s price is currently Overvalued.
Does Argenica Therapeutics Ltd pay dividends?
Argenica Therapeutics Ltd does not currently pay dividends.
What is Argenica Therapeutics Ltd’s EPS estimate?
Argenica Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argenica Therapeutics Ltd have?
Argenica Therapeutics Ltd has 128,456,710 shares outstanding.
What happened to Argenica Therapeutics Ltd’s price movement after its last earnings report?
Argenica Therapeutics Ltd reported an EPS of -AU$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.754%.
Which hedge fund is a major shareholder of Argenica Therapeutics Ltd?
Currently, no hedge funds are holding shares in AU:AGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argenica Therapeutics Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.48%
12-Months-Change
Fundamentals
Return on Equity
-183.51%
Trailing 12-Months
Asset Growth
-66.25%
Trailing 12-Months
Company Description
Argenica Therapeutics Ltd
Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. The company was incorporated in 2019 and is based in Nedlands, Australia.
Technical Analysis
Alterity Therapeutics
―
Race Oncology Ltd.
―
Nanollose Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Options Prices
Currently, No data available
---